<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0409234106
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ALENDRO
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALENDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        43.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alendro<sup>TM</sup> belongs to a group of non-hormonal medicines called bisphosphonates.<br />Alendro<sup>TM</sup> prevents the loss of bone that occurs in women after they have been<br />through the menopause, and helps to rebuild bone. It reduces the risk of spine and hip<br />fractures.<br /><strong>What is Alendro<sup>TM</sup> 70mg used for</strong><br />Your doctor has prescribed Alendro<sup>TM</sup>to treat your osteoporosis. Alendro<sup>TM</sup>reduces<br />the risk of spine and hip fractures.<br /><strong>Alendro<sup>TM</sup> 70mg is a once weekly treatment.<br />What is osteoporosis?</strong><br />Osteoporosis is a thinning and weakening of the bones. It is common in women after<br />the menopause. At the menopause, the ovaries stop producing the female hormone,<br />oestrogen, which helps to keep a woman&rsquo;s skeleton healthy. As a result, bone loss<br />occurs and bones become weaker. The earlier a woman reaches the menopause, the<br />greater the risk of osteoporosis.<br />Early on, osteoporosis usually has no symptoms. If left untreated, however, it can<br />result in broken bones. Although these usually hurt, breaks in the bones of the spine<br />may go unnoticed until they cause height loss. Broken bones can happen during<br />normal, everyday activity, such as lifting, or from minor injury that would not<br />generally break normal bone. Broken bones usually occur at the hip, spine, or wrist<br />and can lead not only to pain but also to considerable problems like stooped posture<br />(&lsquo;dowager&rsquo;s hump&rsquo;) and loss of mobility.<br /><strong>How can osteoporosis be treated?</strong><br />Osteoporosis can be treated and it is never too late to begin treatment. Alendro<sup>TM</sup> not<br />only prevents the loss of bone but actually helps to rebuild bone you may have lost<br />and reduces the risk of bones breaking in the spine and hip.<br />As well as your treatment with Alendro<sup>TM</sup>, your doctor may suggest you make<br />changes to your lifestyle to help your condition, such as:<br />Stopping smoking: Smoking appears to increase the rate at which you lose bone and,<br />therefore, may increase your risk of broken bones.<br />Exercise: Like muscles, bones need exercise to stay strong and healthy. Consult your<br />doctor before you begin any exercise programme.<br />Eating a balanced diet: Your doctor can advise you about your diet or whether you<br />should take any dietary supplements (especially calcium and Vitamin D).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Alendro<sup>TM</sup> 70mg</strong><br />(1) if you&nbsp; are allergic hypersensitive) to alendronate sodium trihydrate or any of the&nbsp;<br />other ingredients (listed in Section 6: Further information).<br />(2) if you have certain problems with your gullet (oesophagus the tube that connects your mouth&nbsp;<br />with your stomach) such as narrowing or difﬁculty swallowing.<br />(3) if you cannot stand or sit upright for at least 30 minutes.<br />(4) if your doctor has told you that you have low blood calcium.<br />If you think any of these apply to you, do not take the tablets. Talk to your doctor ﬁrst and&nbsp;<br />follow the advice given.<br /><strong>Take special care with Alendro<sup>TM</sup> 70mg</strong><br />It is important to tell your doctor before taking Alendro<sup>TM</sup> if:<br />&bull; you suffer from kidney problems,<br />&bull; you have any swallowing or digestive problems,<br />&bull; your doctor has told you that you have Barrett&#39;s oesophagus (a condition associated with changes&nbsp;<br />in the cells that line the lower oesophagus),<br />&bull; you have been told you have low blood calcium,<br />&bull; you have poor dental health, gum disease, a planned dental extraction or you don&#39;t receive&nbsp;<br />routine dental care,<br />&bull; you have cancer,<br />&bull; you are undergoing chemotherapy or radiotherapy,<br />&bull; you are taking corticosteroids (such as prednisone or dexamethasone),<br />&bull; you are or have been a smoker (as this may increase the risk of dental problems).<br />You may be advised to have a dental check-up before starting treatment with Alendro<sup>TM</sup> .<br />It is important to maintain good oral hygiene when being treated with Alendro<sup>TM</sup> . You should have&nbsp;<br />routine dental check-ups throughout your treatment and you should contact your doctor or dentist if&nbsp;<br />you experience any problems with your mouth or teeth such as loose teeth, pain or swelling.<br />Irritation, inﬂammation or ulceration of the gullet (oesophagus-the tube that connects your mouth&nbsp;<br />with your stomach) often with symptoms of chest pain, heartburn, or difﬁculty or pain upon&nbsp;<br />swallowing may occur, especially if patients do not drink a full glass of water and/or if they lie&nbsp;<br />down less than 30 minutes after taking Alendro<sup>TM</sup> . These side effects may worsen if patients&nbsp;<br />continue to take Alendro<sup>TM</sup> after developing these symptoms.<br /><strong>Taking other medicines</strong><br />It is likely that calcium supplements, antacids, and some oral medicines will interfere with the&nbsp;<br />absorption of Alendro<sup>TM</sup> if taken at the same time. Therefore, it is important that you follow the&nbsp;<br />advice given in (section 3. How to take Alendro<sup>TM</sup> 70mg).<br />Certain medicines for rheumatism or long-term pain called NSAIDs (e.g. aspirin or ibuprofen) might&nbsp;<br />cause digestive problems. Therefore, caution should be used when these medicines are taken at the&nbsp;<br />same time as Alendro<sup>TM</sup> .<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines,&nbsp;<br />including medicines obtained without a prescription.<br /><strong>Taking Alendro<sup>TM</sup> 70mg with food and drink</strong><br />It is likely that food and beverages (including mineral water) will make Alendro<sup>TM</sup> less effective&nbsp;<br />if taken at the same time. Therefore, it is important that you follow the advice given in section&nbsp;<br />3. How to take Alendro<sup>TM</sup> 70mg.<br /><strong>Children and adolescents</strong><br />Alendro<sup>TM</sup> &nbsp;should not be given to children and adolescents.<br /><strong>Pregnancy and breast-feeding</strong><br />Alendro<sup>TM</sup> is only intended for use in postmenopausal women. You should not take Alendro<sup>TM</sup> if you&nbsp;<br />are or think you may be pregnant, or if you are breast-feeding.<br /><strong>Driving and using machines</strong><br />There have been side effects (including blurred vision, dizziness and severe bone, muscle or joint&nbsp;<br />pain) reported with AlendroTM &nbsp;that may affect your ability to drive or operate machinery.&nbsp;<br />Individual responses to AlendroTM &nbsp;may vary (See 4. Possible Side effects.).<br /><strong>Important information about some of the ingredients of Alendro<sup>TM</sup> &nbsp; &nbsp;</strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />Alendro<sup>TM</sup> contains lactose. If you have been told by your doctor that you have an<br />intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Take one Alendro<sup>TM</sup> 70mg tablet once a week.</strong><br />Follow these instructions carefully to make sure you will benefit from Alendro<sup>TM</sup>.<br />1) Choose the day of the week that best fits your schedule. Every week, take one<br />Alendro<sup>TM&nbsp;</sup>tablet on your chosen day.<br />It is very important to follow instructions 2), 3), 4) and 5) to help the Alendro<sup>TM</sup><br />tablet reach your stomach quickly and help reduce the chance of irritating your gullet<br />(oesophagus-the tube that connects your mouth with your stomach).<br />2) After getting up for the day and before taking any food, drink, or other medicine,<br />swallow your AlendroTM tablet whole with a full glass of water only (not mineral<br />water) (not less than 200 ml or 7 fl. oz.).<br />&bull; Do not take with mineral water (still or sparkling).<br />&bull; Do not take with coffee or tea.<br />&bull; Do not take with juice or milk.<br />&bull; Do not crush or chew the tablet or allow it to dissolve in your mouth.<br />3) Do not lie down-stay fully upright (sitting, standing or walking)-for at least 30<br />minutes after swallowing the tablet. Do not lie down until after your first food of the day.<br />4) Do not take Alendro<sup>TM&nbsp;</sup>at bedtime or before getting up for the day.<br />5) If you develop difficulty or pain upon swallowing, chest pain, or new or worsening<br />heartburn, stop taking Alendro<sup>TM&nbsp;</sup>and contact your doctor.<br />6) After swallowing your Alendro<sup>TM&nbsp;</sup>tablet, wait at least 30 minutes before taking your first food, drink, or other medicine of the day, including antacids, calcium<br />supplements and vitamins. AlendroTM is effective only if taken when your stomach is empty.<br /><strong>If you take more Alendro<sup>TM</sup> 70mg than you should</strong><br />If you take too many tablets by mistake, drink a full glass of milk and contact your<br />doctor immediately. Do not make yourself vomit, and do not lie down.<br /><strong>If you forget to take Alendro<sup>TM</sup> 70mg</strong><br />If you miss a dose, just take one tablet on the morning after you remember. Do not<br />take two tablets on the same day. Return to taking one tablet once a week, as<br />originally scheduled on your chosen day.<br /><strong>If you stop taking Alendro<sup>TM</sup> 70mg</strong><br />It is important that you continue taking AlendroTM for as long as your doctor<br />prescribes the medicine. AlendroTM can treat your osteoporosis only if you continue to<br />take the tablets.<br />If you have any further questions on the use of this product, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, AlendroTM can cause side effects, although not everybody gets them.<br />The following terms are used to describe how often side effects have been reported.<br />Very common (occurring in at least 1 of 10 patients treated).<br />Common (occurring in at least 1 of 100 and less than 1 of 10 patients treated).<br />Uncommon (occurring in at least 1 of 1,000 and less than 1 of 100 patients treated).<br />Rare (occurring in at least 1 of 10,000 and less than 1 of 1,000 patients treated).<br />Very rare (occurring in less than 1 of 10,000 patients treated).<br />Very common:<br />&bull; bone, muscle and/or joint pain which is sometimes severe.<br />Common:<br />&bull; heartburn;difficulty swallowing;pain upon swallowing;ulceration of the gullet<br />(oesophagus-the tube that connects your mouth with your stomach) which can cause<br />chest pain, heartburn or difficulty or pain upon swallowing,<br />&bull; joint swelling,<br />&bull; abdominal pain;uncomfortable feeling in the stomach or belching after eating;<br />constipation; full or bloated feeling in the stomach; diarrhoea; flatulence,<br />&bull; hair loss; itching,<br />&bull; headache; dizziness,<br />&bull; tiredness; swelling in the hands or legs.<br />Uncommon:<br />&bull; nausea; vomiting,<br />&bull; irritation or inflammation of the gullet (oesophagus the tube that connects your<br />mouth with your stomach) or stomach,<br />&bull; black or tar-like stools,<br />&bull; blurred vision; pain or redness in the eye,<br />&bull; rash; redness of the skin,<br />&bull; transient flu-like symptoms, such as aching muscles, generally feeling unwell and<br />sometimes with fever usually at the start of treatment,<br />&bull; taste disturbance.<br />Rare:<br />&bull; allergic reactions such as hives; swelling of the face, lips, tongue and/or throat,<br />possibly causing difficulty breathing or swallowing,<br />&bull; symptoms of low blood calcium levels including muscle cramps or spasms and/or<br />tingling sensation in the fingers or around the mouth,<br />&bull; stomach or peptic ulcers (sometimes severe or with bleeding),<br />&bull; narrowing of the gullet (oesophagus-the tube that connects your mouth with your<br />stomach),<br />&bull; rash made worse by sunlight; severe skin reactions,<br />&bull; pain in the mouth, and/or jaw, swelling or sores inside the mouth, numbness or a<br />feeling of heaviness in the jaw, or loosening of a tooth. These could be signs of bone<br />damage in the jaw (osteonecrosis) generally associated with delayed healing and<br />infection, often following tooth extraction. Contact your doctor and dentist if you<br />experience such symptoms,<br />&bull; unusual fracture of the thigh bone particularly in patients on long-term treatment for<br />osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness<br />or discomfort in your thigh, hip or groin as this may be an early indication of a<br />possible fracture of the thigh bone,<br />&bull; mouth ulcers when the tablets have been chewed or sucked.<br />Tell your doctor or pharmacist promptly about these or any other unusual symptoms.<br />It will help if you make a note of what you experienced, when it started and how long<br />it lasted.<br />If any of the side effects gets serious, or if you notice any side effects not listed in this<br />leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30&deg;C.<br />&bull; Do not remove the tablets from the blister pack until you are ready to take the medicine.<br />&bull; Do not use after the expiry date (EXP) which is stated on the blister strip and the carton.<br />&bull; Medicines should not be disposed of via waste water or household waste. Ask your<br />&nbsp; pharmacist how to dispose of medicines no longer required. This will help to protect<br />&nbsp; the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Alendro<sup>TM</sup> 70mg contains</strong><br />The active substance is alendronate sodium trihydrate. Each tablet contains 70 mg<br />alendronic acid as alendronate sodium trihydrate.<br />The other ingredients are colloidal silicon dioxide, croscarmellose sodium,<br />lactose, magnesium stearate and microcrystalline cellulose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                AlendroTM tablets are white to off white, round, biconvex tablets, engraved with
'JP 38' on one side and plain on the other side.
Alendro™ 70 mg tablets are available in a box containing 4 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111 Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />Please report adverse drug events to:<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />o Fax: +966-11-205-7662<br />o SFDA Call Center: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12505653 - Rev. 03/22-08-2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>أليندرو ينتمى إلى مجموعة من الأدوية الغير هرمونية تسمى البيسفوسفونيت.&nbsp;<br />يمنع فقدان العظام الذى يحدث للسيدات بعد انقطاع الطمث ، كما يساعد فى إعادة بناء العظام و &trade; أليندرو<br />يقلل من خطر الإصابة بكسور العمود الفقرى و الفخذين.<br />&nbsp;فيما يستخدم أليندرو<br />لقد قام طبيبك بوصف أليندرو لك لعلاج هشاشة العظام.&nbsp;<br />&nbsp;أليندرو يقلل من خطر الإصابة بكسور العمود الفقرى و الفخذين.&nbsp; أليندرو هو دواء يؤخذ مرة واحدة أسبوعياً.</p><p>ما هى هشاشة العظام؟<br />هشاشة العظام هي ترقق و ضعف العظام و تكون شائعة الحدوث فى السيدات بعد انقطاع الطمث . عند<br />انقطاع الطمث، تتوقف المبايض عن انتاج الهرمون الأنثوى الإستروجين و الذى يساعد فى الحفاظ على<br />صحة الهيكل العظمى للمرأة . نتيجة لهذا يحدث فقدان للعظام و تصبح العظام أكثر ضعفا . كلما حدث<br />انقطاع الطمث فى سن مبكر كلما ازداد خطر الإصابة بهشاشة العظام.<br />فى المراحل المبكرة للمرض، عادة لا تظهر أى أعراض لهشاشة العظام ، لكن إذا تُركت من دون علاج، قد<br />يؤدى ذلك إلى كسور فى العظام. بالرغم من أن هذه الكسور عادة ما يصاحبها الشعور بالألم إلا أن الكسور<br />فى عظام العمود الفقرى قد لا يُلاحظ حدوثها حتى تسبب إنحناء القامة.<br />كسور العظام قد تحدث أثناء القيام بالأنشطة اليومية المعتادة مثل رفع الأشياء أو عن طريق الإصابات<br />الطفيفة التى لا تؤدى فى العادة إلى حدوث كسور فى العظام.<br />الكسور عادة ما تحدث فى عظام الفخذين، العمود الفقرى أو الرسغ فيتسبب هذا ليس فقط فى الشعور بالألم<br />ولكن أيضا مشاكل كبيرة مثل الإنحناء أثناء الوقوف (حدبة الأرملة) و فقدان القدرة على الحركة.<br />كيف يتم علاج هشاشة العظام؟<br />لا يمنع فقط &trade; من الممكن علاج هشاشة العظام و لا يوجد هناك وقت متأخر لعلاج هشاشة العظام. أليندرو<br />خسارة العظام و لكنه يقوم فعليا بإعادة بناء العظام التى فقدت و يقلل من خطر حدوث كسور فى عظام<br />الفخذين و عظام العمود الفقرى.<br />قد يقترح طبيبك عليك إجراء بعض التغييرات فى نمط الحياة الخاص بك للمساعدة &trade; بجانب العلاج بأليندرو<br />فى علاج حالتك مثل:<br />التوقف عن التدخين<br />يبدو أن التدخين يزيد من معدل فقدان العظام و نتيجة لذلك قد يزيد من خطر الإصابة بكسور العظام.<br />ممارسة الأنشطة الرياضية<br />مثل العضلات، تحتاج العظام للأنشطة الرياضية لتحافظ على قوتها و صحتها. استشر طبيبك قبل البدء بأى<br />برنامج رياضى.<br />تناول غذاء متوازن<br />سوف ينصحك طبيبك بشأن غذائك أو إذا وجب عليك أن تتناول أى مكملات غذائية خاصة الكالسيوم و<br />ڤيتامين د.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أليندرو فى الحالات الآتية:&nbsp;<br />&bull; إذا كنت تعانى من حساسية مفرطة لأليندرونات صوديوم ترايهيدرات أو لأى من المكونات الأخرى لهذا<br />الدواء (المذكورة فى الجزء رقم ٦ من هذه النشرة).<br />&bull; إذا كنت تعانى من مشكلة معينة فى المرىء (وهو أنبوب يصل بين الفم و المعدة) مثل الضيق أو الصعوبة<br />فى البلع.<br />&bull; إذا كنت لا تستطيع الوقوف أو الجلوس فى وضع أفقى لمدة تقل عن ۳۰ دقيقة.<br />&bull; إذا أخبرك طبيبك أنك تعانى من انخفاض الكالسيوم فى الدم.<br />إذا انطبقت عليك إحدى الحالات السابق ذكرها، لا تتناول هذه الأقراص. تحدث إلى طبيبك أولا ثم اتبع<br />النصيحة.<br />أعط عناية خاصة عند تناول&nbsp; أليندروفى الحالات الآتية:&nbsp;<br />يرجى إخبار الطبيب قبل البدء فى تناول أليندرو فى الحالات الآتية:&nbsp;<br />&bull; تعانى من مشاكل فى الكلى.<br />&bull; لديك أى مشاكل فى البلع أو فى الهضم.<br />&bull; قد أخبرك طبيبك بأنك تعانى من مرىء باريت (حالة يصاحبها تغيرات فى الخلايا التى تبطن أسفل<br />المرىء).<br />&bull; قد تم إخبارك بانخفاض مستوى الكالسيوم فى دمك.<br />&bull; لديك أسنان غير صحية ، مرض فى اللثة، قمت بخلع أسنان أو لا تقم برعاية لأسنانك.<br />&bull; تعانى من مرض السرطان.<br />&bull; تتلقى العلاج الكيميائى أو العلاج الإشعاعى.<br />&bull; تتناول السترويدات القشرية (الكورتيزون) مثل بريدنيزون و ديكساميثازون.<br />&bull; أنت مدخن أو كنت تدخن فى الماضى لأن هذا قد يزيد خطر الإصابة بمشاكل الأسنان.<br />&nbsp;قد تُنصح بإجراء فحص طبى للأسنان قبل البدء فى العلاج بأليندرو<br />من المهم الحفاظ على النظافة الجيدة للفم أثناء العلاج بأليندرو يجب أن تجرى فحوصات طبية للفم بانتظام .<br />أثناء فترة علاجك و يجب أن تتصل بالطبيب أو بطبيب الأسنان إذا حدثت لك أى مشاكل فى الفم أو فى<br />الأسنان مثل تخلخل الأسنان، الألم أو التورم.<br />تهيج ، التهاب أو تقرح المرىء (وهو أنبوب يصل بين الفم و المعدة) غالبا ما يصاحبه أعراض مثل ألم<br />الصدر، حموضة المعدة، صعوبة أو ألم عند البلع خاصة عند الأشخاص الذين لا يشربون كوب كامل من<br />بعد تناول أليندرو قد تزداد هذه الأعراض سوءا إذا ما استمر . الماء و/ أو يستلقون لمدة أقل من ۳۰ دقيقة<br />بعد حدوثها. &trade; المريض فى تناول أليندرو<br />تناول أدوية أخرى<br />مكملات الكالسيوم، مضادات الحموضة و بعض الأدوية التى تؤخذ عن طريق الفم قد تؤثر على امتصاص<br />. إذا ما تم تناولهم فى نفس الوقت. لذلك يجب أن تتبع النصائح المذكورة فى الجزء رقم ۳&nbsp;<br />بعض الأدوية التى تستخدم لعلاج الروماتيزم أو الألم طويل الأمد المسماة مضادات الإلتهاب غير السترويدية<br />مثل الأسبرين او الإبيوبرفين قد تسبب مشاكل فى الهضم. لذلك يجب توخى الحذر عند تناول هذه الأدوية فى&nbsp;نفس الوقت مع أليندرو<br />يرجى إخبار الطبيب أو الصيدلى إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى. هذا يشمل الأدوية التى<br />يمكنك شراؤها بدون تذكرة طبية.<br />مع الطعام و الشراب &trade; تناول أليندرو<br />إذا ما تم تناولهم فى نفس &trade; من المحتمل أن يقلل الطعام و المشروبات و المياه المعدنية من مفعول أليندرو<br />لذلك يجب أن تتبع النصائح المذكورة فى الجزء رقم ۳<br />الأطفال و المراهقين<br />لا يجب إعطاء أليندرو للأطفال و المراهقين.&nbsp;<br />الحمل و الرضاعة<br />أليندرو يعطى فقط للسيدات بعد إنقطاع الطمث.<br />لا يجب أن تتناولى أليندرو إذا كنتِ حاملا أو تشكين فى كونك حاملا أو إذا كنتِ مرضعة.&nbsp;<br />قيادة المركبات و تشغيل الآلات<br />قد تم الإبلاغ عن بعض الآثار الجانبية لأليندرو و التى قد تؤثر فى قدرتك على القيادة و تشغيل الآلات مثل&nbsp;&nbsp;<br />عدم وضوح الرؤية، الدوار و ألم شديد فى العظام، العضلات أو المفاصل.<br />قد تختلف الإستجابات الفردية لأليندرو انظر إلى جزء ٤.الآثار الجانبية المحتملة).&nbsp;<br />&nbsp;معلومة هامة عن بعض مكونات أليندرو<br />يحتوى على اللاكتوز. إذا ما تم إخبارك بأنه لا يمكنك هضم بعض السكريات،</p><p>تحدث إلى طبيبك قبل البدء فى تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;اتبع التعليمات الآتية بعناية للتحقق من تحقيق الإستفادة القصوى من أقراص أليندرو<br />خذ قرص واحد من أليندرو في اليوم الذى قمت&nbsp;باختياره 1 كل أسبوع ، .&nbsp;اختر يوم من أيام الأسبوع يناسبك .<br />لجعل قرص أليندرو يصل إلى المعدة بشكل أسرع&nbsp;من المهم جداً أن تتبع التعليمات رقم 2,3,4,5<br />تقليل تهيج المرىء (وهو أنبوب يصل بين الفم و المعدة).<br />۲. فى الصباح و قبل تناول أى طعام ، شراب أو أى أدوية أخرى ، قم ببلع القرص كاملاً مع كوب من الماء<br />فقط (ليس ماءً معدنياً)(لا تستخدم أقل من ۲۰۰ مل أو ۷ أونصة من الماء).<br />&bull; لا تبلع القرص باستخدام المياه المعدنية. (ثابتة أو فوارة).<br />&bull; لا تبلع القرص باستخدام القهوة أو الشاى.<br />&bull; لا تبلع القرص باستخدام العصير أو الحليب.<br />لا تقم بسحق أو مضغ الأقراص أو تتركها تذوب فى فمك.<br />۳. لا تستلق و حافظ على استقامتك أثناء الجلوس، الوقوف أو المشى لمدة ۳۰ دقيقة على الأقل بعد بلع<br />القرص. لا تستلق حتى تتناول وجبتك الأولى فى اليوم.<br />٤. لا تتناول أليندرو وقت النوم أو قبل نهوضك للنشاط اليومي.&nbsp;<br />٥. إذا شعرت بصعوبة أو ألم عند البلع، ألم فى الصدر أو ظهور أعراض حموضة المعدة أو تفاقمها ، توقف<br />و اتصل بطبيبك.&nbsp;</p><p>بعد&nbsp;بلع قرص أليندروانتظر على الأقل ۳۰ دقيقة قبل تناول طعامك الأول فى اليوم، شرابك أو أى أدوية أخرى بما فيها مضادات &nbsp;الحموضة، مكملات الكالسيوم والڤيتامينات.<br />أليندرو يكون فعال فقط إذا ما تم تناوله و معدتك فارغة.<br />إذا كنت تتناول أليندرو أكثر مما ينبغى:&nbsp;<br />إذا تناولت العديد من الأقراص عن طريق الخطأ، قم بشرب كوب كامل من الحليب و اتصل على الفور<br />بالطبيب. لا تجبر نفسك على التقيؤ و لا تستلقى.<br />إذا نسيت أن تتناول أليندرو:<br />إذا نسيت أن تتناول جرعة من أليندرو خذ قرص واحد فى الصباح بعد تذكرك . لا تتناول قرصين فى نفس اليوم. عد إلى تناول قرص واحد أسبوعياً كما اعتدت فى اليوم الذى قمت باختياره.<br />&nbsp;إذا توقفت عن تناول أليندرو<br />أليندرو &trade; يعالج هشاشة العظام فقط إذا&nbsp;من المهم أن تستمر فى تناول أليندرو&nbsp; طوال المدة التى حددها طبيبك.<br />ما استمريت فى تناول الأقراص.<br />إذا كان لديك أية أسئلة أخرى عن استخدام هذا الدواء ، إسأل الطبيب أو الصيدلى .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>من المحتمل ظهور أعراض جانبية لأليندرو لكنها لا تصيب كل الأشخاص.&nbsp;كما هو الحال مع جميع الأدوية ،<br />مدى شيوع الآثار الجانبية المذكورة بالأسفل تم التعبير عنها باستخدام المصطلحات الآتية:<br />آثار جانبية شائعة جدا: تصيب على الأقل ۱ من كل ۱۰ أشخاص يستخدمون هذا الدواء.<br />آثار جانبية شائعة: تصيب على الأقل ۱ من كل ۱۰۰ شخص و أقل من ۱ من كل ۱۰ شخص يستخدم هذا<br />الدواء.<br />آثار جانبية غير شائعة: تصيب على الأقل ۱ من كل ۱۰۰۰ و أقل من ۱ من كل ۱۰۰ شخص يستخدم هذا<br />الدواء.<br />آثار جانبية نادرة: تصيب على الأقل ۱ من كل ۱۰۰۰۰ و أقل من ۱ من كل ۱۰۰۰ شخص يستخدم هذا<br />الدواء.<br />آثار جانبية نادرة جدا: تصيب أقل من ۱ من كل ۱۰۰۰۰ شخص يستخدمون هذا الدواء.<br />أعراض جانبية شائعة جدا<br />&bull; ألم فى العظم، العضلات و / أو المفاصل و الذى يكون فى بعض الأحيان شديد جدا.<br />أعراض جانبية شائعة<br />&bull; حموضة المعدة، صعوبة فى البلع، ألم عند البلع، تقرح المرىء (وهو أنبوب يصل بين الفم و المعدة) مما<br />يسبب ألم فى الصدر، حرقان أو صعوبة أو ألم عند البلع.<br />&bull; تورم المفاصل.<br />&bull; ألم البطن، شعور غير مريح فى المعدة أو التجشوء بعد الأكل ، إسهال، الشعور بالإمتلاء أو إنتفاخ المعدة،<br />إسهال، إنتفاخ البطن.<br />&bull; فقدان الشعر، حكة.<br />&bull; صداع، دوار.<br />&bull; إرهاق و تورم اليدين أو القدمين.<br />أعراض جانبية غير شائعة<br />&bull; غثيان و قىء.<br />&bull; تهيج أو التهاب المرىء أو المعدة.<br />&bull; براز أسود اللون أو قطرانى.<br />&bull; عدم وضوح الرؤية، ألم أو إحمرار العينين.<br />&bull; طفح جلدى، إحمرار الجلد.<br />&bull; أعراض شبيهه بأعراض الإنفلونزا مثل ألم العضلات، الشعور العام بالإعياء و الحمى أحيانا و عادة ما<br />يكون هذا فى بداية العلاج.<br />&bull; تغير فى حاسة التذوق.<br />أعراض جانبية نادرة<br />&bull; حساسية مثل الطفح الجلدى ، تورم الوجه، الشفتين، اللسان و / أو الحلق مما قد يسبب صعوبة فى التنفس<br />أو البلع.<br />&bull; أعراض نقص مستويات الكالسيوم تشمل تشنجات أو تقلصات العضلات و / أو الشعور بالوخز فى<br />الأصابع أو حول الفم.<br />&bull; قرحة المعدة أو الجهاز الهضمي ( في بعض الأحيان تكون شديدة أو مع نزيف)،<br />&bull; تضييق المريء (المريء-الأنبوب الذي يربط الفم مع المعدة)،<br />&bull; طفح جلدى يزداد سوءا عند التعرض للأشعة الشمس، حساسية شديدة للشمس.<br />&bull; ألم فى الفم و / أو الفك ، تورم أو تقرح داخل الفم، تنميل أو الشعور بثقل فى الفك أو فقدان الأسنان قد تكون<br />هذه الأشياء دليل على حدوث ضرر لعظام الفك (تنخر العظم) و غالبا ما يصاحبه تأخر إلتئام الجروح و<br />الإصابة بالعدوى بعد خلع الأسنان . اتصل بالطبيب أو بطبيب الأسنان إذا عانيت من هذه الأعراض.<br />&bull; كسر غير عادى فى عظام الفخذ خاصة فى المرضى الذين يتناولون علاج طويل الأمد لهشاشة العظام و<br />هذا يحدث فى حالات نادرة . اتصل بطبيبك إذا عانيت من ألم، ضعف أو شعور بعدم الراحة فى الفخذ،<br />الحوض أو الأربية لأن هذا قد يكون مؤشر مبكر لكسر محتمل فى عظمة الفخذ.<br />&bull; قرح الفم عندما يتم مضغ أو لعق الأقراص.<br />اخبر طبيبك على الفور عن هذه الأعراض أو عن أى أعراض أخرى غير عادية.<br />من المفضل أن تقوم بتسجيل الأعراض الجانبية التى حدثت لك ، متى بدأت و كم استمرت.<br />إذا وصلت أحد الآثار الجانبية لهذا الدواء لمرحلة الخطر أو ظهرت آثار جانبية جديدة لم تذكر في هذه النشرة<br />يرجى اخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيداً عن متناول و مرأى الأطفال.<br />م. &ordm; &bull; يحفظ فى درجة حرارة لا تزيد عن ۳۰<br />&bull; لا تتناول أقراص أليندرو بعد انتهاء فترة صلاحيتها المكتوبة&nbsp;على الشرائط و العلبة بعد كلمة . EXP<br />&bull; لا تنزع الأقراص من الشرائط إلا عند استخدامها.<br />&bull; اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها .لا ينبغي التخلص من الأدوية عبر<br />إلقائها فى بالوعات الصرف أو فى مخلفات المنزل . ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة<br />المادة الفعالة هى أليندرونات صوديوم ترايهيدرات . كل قرص يحتوى على ۷۰ مجم من حمض الأليندرونيك<br />فى صورة أليندرونات صوديوم ترايهيدرات.<br />المواد الأخرى<br />ثاني أكسيد السيليكون الغروي، لاكتوز، كروسكرميللوز صوديوم، ستيرات المغنيسيوم والسليلوز دقيق<br />التبلور.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">&nbsp;أقراص أليندرو لونها أبيض إلى مائل للأبيض، دائرية، محدبة الوجهين، محفور على أحد الجانبين &#39;JP 38&#39; ومستوية علي الجانب الآخر.<br />أقراص أليندرو ۷۰ مجم، متوفرة في عبوة تحتوى على ٤ أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اسم وعنوان مالك رخصة التسویق و المصنع:<br />شركة مصنع جمجوم للأدویة ،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- الھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />:(NPC) المركز الوطني للتیقظ الدوائي<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />مركز اتصال الھیئة العامة للغذاء والدواء: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />https://ade.sfda.gov.sa : الموقع الالكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12505653 - Rev. 03/22-08-2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alendro 70 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 70 mg alendronic acid (as sodium trihydrate).
Excipients with known effect
Each tablet contains 161.88 mg lactose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
White to off white, round, biconvex uncoated tablets about 9.5 mm, engraved with 'JP 38' on one side
and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alendro is indicated in adults for the treatment of postmenopausal osteoporosis. It reduces the risk of<br />vertebral and hip fractures.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The recommended dosage is one 70 mg tablet once weekly.<br />Patients should be instructed that if they miss a dose of Alendro Once Weekly, they should take one<br />tablet on the morning after they remember. They should not take two tablets on the same day but<br />should return to taking one tablet once a week, as originally scheduled on their chosen day.<br />The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need<br />for continued treatment should be re-evaluated periodically based on the benefits and potential risks of<br />&#39;Alendronate &#39; on an individual patient basis, particularly after 5 or more years of use.</p><p>Elderly<br />In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate.<br />Therefore no dosage adjustment is necessary for the elderly.<br />Renal impairment<br />No dosage adjustment is necessary for patients with creatinine clearance greater than 35 ml/min.<br />Alendronate is not recommended for patients with renal impairment where creatinine clearance is less<br />than 35 ml/min, due to lack of experience.</p><p>Paediatric population<br />The safety and efficacy of Alendronate in children less than 18 years of age has not been established.<br />This medicinal product should not be used in children less than 18 years of age. Currently available<br />data for alendronic acid in the paediatric population is described in section 5.1.<br />Method of administration<br />Oral use.<br />To permit adequate absorption of alendronate:</p><p>Alendronate must be taken at least 30 minutes before the first food, beverage, or medicinal product of<br />the day with plain water only. Other beverages (including mineral water), food and some medicinal<br />products are likely to reduce the absorption of alendronate (see section 4.5).<br />To facilitate delivery to the stomach and thus reduce the potential for local and oesophageal<br />irritation/adverse experiences (see section 4.4):<br />- Alendronate should only be swallowed upon arising for the day with a full glass of water (not less<br />than 200 ml).<br />- Patients should only swallow Alendronate whole. Patients should not crush or chew the tablet or<br />allow the tablet to dissolve in their mouths because of a potential for oropharyngeal ulceration.<br />- Patients should not lie down for at least 30 minutes after taking Alendronate and until after the first<br />food of the day.<br />- Alendronate should not be taken at bedtime or before arising for the day.<br />Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate (see section 4.4).<br />Alendronate Once Weekly 70 mg has not been investigated in the treatment of glucocorticoid-induced osteoporosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Abnormalities of the esophagus and other factors which delay esophageal emptying such as
stricture or achalasia.
- Inability to stand or sit upright for at least 30 minutes.
- Hypocalcaemia.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Upper gastrointestinal adverse reactions<br />Alendronate can cause local irritation of the upper gastro-intestinal mucosa. Because there is a potential<br />for worsening of the underlying disease, caution should be used when alendronate is given to patients<br />with active upper gastro-intestinal problems, such as dysphagia, oesophageal disease, gastritis,<br />duodenitis, ulcers, or with a recent history (within the previous year) of major gastro-intestinal disease<br />such as peptic ulcer, or active gastro-intestinal bleeding, or surgery of the upper gastro-intestinal tract<br />other than pyloroplasty (see section 4.3). In patients with known Barrett&#39;s oesophagus, prescribers<br />should consider the benefits and potential risks of alendronate on an individual patient basis.</p><p><br />Oesophageal reactions (sometimes severe and requiring hospitalisation), such as oesophagitis,<br />oesophageal ulcers and oesophageal erosions, rarely followed by oesophageal stricture, have been<br />reported in patients receiving alendronate. Physicians should therefore be alert to any signs or<br />symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue<br />alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as<br />dysphagia, pain on swallowing or retrosternal pain, new or worsening heartburn (see section 4.8).</p><p>The risk of severe oesophageal adverse experiences appears to be greater in patients who fail to take<br />alendronate properly and/or who continue to take alendronate after developing symptoms suggestive of<br />oesophageal irritation. It is very important that the full dosing instructions are provided to, and<br />understood by the patient (see section 4.2). Patients should be informed that failure to follow these<br />instructions may increase their risk of oesophageal problems.</p><p>While no increased risk was observed in extensive clinical trials, there have been rare (post-marketing)<br />reports of gastric and duodenal ulcers, some severe and with complications (see section 4.8).</p><p><br />Osteonecrosis of the jaw<br />Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including<br />osteomyelitis), has been reported in patients with cancer who are receiving treatment regimens<br />including primarily intravenously administered bisphosphonates. Many of these patients were also<br />receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw has also been reported in patients<br />with osteoporosis receiving oral bisphosphonates.</p><p>The following risk factors should be considered when evaluating an individual&#39;s risk of developing<br />osteonecrosis of the jaw:<br />&bull; potency of the bisphosphonate (highest for zoledronic acid), route of administration (see above) and<br />cumulative dose<br />&bull; cancer, chemotherapy, radiotherapy, corticosteroids, angiogenesis inhibitors, smoking<br />&bull; a history of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures and<br />poorly fitting dentures.<br />A dental examination with appropriate preventive dentistry should be considered prior to treatment<br />with oral bisphosphonates in patients with poor dental status.</p><p>While on treatment, these patients should avoid invasive dental procedures if possible. For patients who<br />develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the<br />condition. For patients requiring dental procedures, there are no data available to suggest whether<br />discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. Clinical<br />judgement of the treating physician should guide the management plan of each patient based on<br />individual benefit/risk assessment.</p><p>During bisphosphonate treatment, all patients should be encouraged to maintain good oral hygiene,<br />receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or<br />swelling.</p><p>Osteonecrosis of the external auditory canal<br />Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly in<br />association with long-term therapy. Possible risk factors for osteonecrosis of the external auditory canal<br />include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The<br />possibility of osteonecrosis of the external auditory canal should be considered in patients receiving<br />bisphosphonates who present with ear symptoms such as pain or discharge, or chronic ear infections.</p><p><br />Musculoskeletal pain<br />Bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates. In post-marketing<br />experience, these symptoms have rarely been severe and/or incapacitating (see section 4.8). The time to<br />onset of symptoms varied from one day to several months after starting treatment. Most patients had<br />relief of symptoms after stopping treatment. A subset had recurrence of symptoms when rechallenged<br />with the same medicinal product or another bisphosphonate.</p><p>Atypical fractures of the femur<br />Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate<br />therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short<br />oblique, fractures can occur anywhere along the femur from just below the lesser trochanter to just<br />above the supracondylar flare. These fractures occur after minimal or no trauma and some patients<br />experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to<br />months before presenting with a complete femoral fracture. Fractures are often bilateral; therefore the<br />contralateral femur should be examined in bisphosphonate-treated patients who have sustained a<br />femoral shaft fracture. Poor healing of these fractures has also been reported. Discontinuation of<br />bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered<br />pending evaluation of the patient, based on an individual benefit risk assessment.</p><p>During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and<br />any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.<br />Renal impairment<br />Alendronate is not recommended for patients with renal impairment where creatinine clearance is less<br />than 35 ml/min, (see section 4.2).<br />Bone and mineral metabolism</p><p>Causes of osteoporosis other than oestrogen deficiency and ageing should be considered.<br />Hypocalcaemia must be corrected before initiating therapy with alendronate (see section 4.3). Other<br />disorders affecting mineral metabolism (such as vitamin D deficiency and hypoparathyroidism) should<br />also be effectively treated before starting this medicinal product. In patients with these conditions,<br />serum calcium and symptoms of hypocalcaemia should be monitored during therapy with Alendronate.<br />Due to the positive effects of alendronate in increasing bone mineral, decreases in serum calcium and<br />phosphate may occur especially in patients taking glucocorticoids in whom calcium absorption may be<br />decreased. These are usually small and asymptomatic. However, there have been rare reports of<br />symptomatic hypocalcaemia, which have occasionally been severe and often occurred in patients with<br />predisposing conditions (e.g. hypoparathyroidism, vitamin D deficiency and calcium malabsorption).<br />Ensuring adequate calcium and vitamin D intake is particularly important in patients receiving<br />glucocorticoids.<br />Excipients<br />This medicinal product contains lactose. Patients with rare hereditary problems of galactose<br />intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this<br />medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If taken at the same time, it is likely that food and beverages (including mineral water), calcium<br />supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate.<br />Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral<br />medicinal product (see sections 4.2 and 5.2).</p><p>No other interactions with medicinal products of clinical significance are anticipated. A number of<br />patients in the clinical trials received oestrogen (intravaginal, transdermal, or oral) while taking<br />alendronate. No adverse experiences attributable to their concomitant use were identified.<br />Since NSAID use is associated with gastrointestinal irritation, caution should be used during<br />concomitant use with alendronate.</p><p>Although specific interaction studies were not performed, in clinical studies alendronate was used<br />concomitantly with a wide range of commonly prescribed medicinal products without evidence of<br />clinical adverse interactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no or limited amount of data from the use of alendronate in pregnant women. Studies in<br />animals have shown reproductive toxicity. Alendronate given during pregnancy in rats caused dystocia<br />related to hypocalcaemia (see section 5.3).<br />Alendronate should not be used during pregnancy.<br />Breast-feeding<br />It is unknown whether alendronate/metabolites are excreted in human milk. A risk to the<br />newborns/infants cannot be excluded. Alendronate should not be used during breast-feeding.<br />Fertility<br />Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over a<br />period of years. The amount of bisphosphonate incorporated into adult bone, and hence, the amount<br />available for release back into the systemic circulation, is directly related to the dose and duration of<br />bisphosphonate use (see section 5.2). There are no data on foetal risk in humans. However, there is a<br />theoretical risk of foetal harm, predominantly skeletal, if a woman becomes pregnant after completing a<br />course of bisphosphonate therapy. The impact of variables such as time between cessation of<br />bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of<br />administration (intravenous versus oral) on the risk has not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alendronate has no or negligible direct influence on the ability to drive and use machines. Patients may<br />experience certain adverse reactions (for example blurred vision, dizziness and severe bone muscle or<br />joint pain (see section 4.8)) that may influence the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />In a one-year study in postmenopausal women with osteoporosis the overall safety profiles of<br />Alendronate Once Weekly 70 mg (n=519) and alendronate 10 mg/day (n=370) were similar.</p><p>In two three-year studies of virtually identical design, in postmenopausal women (alendronate 10 mg:<br />n=196, placebo: n=397) the overall safety profiles of alendronate 10 mg/day and placebo were similar.</p><p>Adverse experiences reported by the investigators as possibly, probably or definitely drug-related are<br />presented below if they occurred in &ge;1% in either treatment group in the one-year study, or in &ge;1% of<br />patients treated with alendronate 10 mg/day and at a greater incidence than in patients given placebo in<br />the three-year studies:</p><table border="1" cellspacing="1" cellpadding="1" style="width:728px"><tbody><tr><td style="width:121px">&nbsp;</td><td rowspan="1" colspan="2" style="text-align:center; width:263px">One-Year Study</td><td rowspan="1" colspan="2" style="width:341px">Three-Year Studies</td></tr><tr><td style="width:121px">&nbsp;</td><td style="width:138px"><p style="text-align:center">Alendronate</p><p style="text-align:center">Once Weekly</p><p style="text-align:center">70mg</p><p style="text-align:center">(n=519)</p><p style="text-align:center">%</p></td><td style="width:124px"><p style="text-align:center">Alendronate</p><p style="text-align:center">10 mg/day</p><p style="text-align:center">(n=370)</p><p style="text-align:center">%</p></td><td style="width:167px"><p style="text-align:center">Alendronate</p><p style="text-align:center">10 mg/day</p><p style="text-align:center">(n=196)</p><p style="text-align:center">%</p></td><td style="width:174px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p style="text-align:center">Placebo</p><p style="text-align:center">(n=397)</p><p style="text-align:center">%</p></td></tr><tr><td style="width:121px"><em>Gastro-intestinal</em></td><td style="width:138px">&nbsp;</td><td style="width:124px">&nbsp;</td><td style="width:167px">&nbsp;</td><td style="width:174px">&nbsp;</td></tr><tr><td style="width:121px">Abdominal pain</td><td style="text-align:center; width:138px">3.7</td><td style="text-align:center; width:124px">3.0</td><td style="text-align:center; width:167px">6.6</td><td style="text-align:center; width:174px">4.8</td></tr><tr><td style="width:121px">Dyspepsia</td><td style="text-align:center; width:138px">2.7</td><td style="text-align:center; width:124px">2.2</td><td style="text-align:center; width:167px">3.6</td><td style="text-align:center; width:174px">3.5</td></tr><tr><td style="width:121px">Acid regurgitation</td><td style="text-align:center; width:138px">1.9</td><td style="text-align:center; width:124px">2.4</td><td style="text-align:center; width:167px">2.0</td><td style="text-align:center; width:174px">4.3</td></tr><tr><td style="width:121px">Nausea</td><td style="text-align:center; width:138px">1.9</td><td style="text-align:center; width:124px">2.4</td><td style="text-align:center; width:167px">3.6</td><td style="text-align:center; width:174px">4.0</td></tr><tr><td style="width:121px">Abdominal distention</td><td style="text-align:center; width:138px">1.0</td><td style="text-align:center; width:124px">1.4</td><td style="text-align:center; width:167px">1.0</td><td style="text-align:center; width:174px">0.8</td></tr><tr><td style="width:121px">Constipation</td><td style="text-align:center; width:138px">0.8</td><td style="text-align:center; width:124px">1.6</td><td style="text-align:center; width:167px">3.1</td><td style="text-align:center; width:174px">1.8</td></tr><tr><td style="width:121px">Diarrhoea</td><td style="text-align:center; width:138px">0.6</td><td style="text-align:center; width:124px">0.5</td><td style="text-align:center; width:167px">3.1</td><td style="text-align:center; width:174px">1.8</td></tr><tr><td style="width:121px">Dysphagia</td><td style="text-align:center; width:138px">0.4</td><td style="text-align:center; width:124px">0.5</td><td style="text-align:center; width:167px">1.0</td><td style="text-align:center; width:174px">0.0</td></tr><tr><td style="width:121px">Flatulence</td><td style="text-align:center; width:138px">0.4</td><td style="text-align:center; width:124px">1.6</td><td style="text-align:center; width:167px">2.6</td><td style="text-align:center; width:174px">0.5</td></tr><tr><td style="width:121px">Gastritis</td><td style="text-align:center; width:138px">0.2</td><td style="text-align:center; width:124px">1.1</td><td style="text-align:center; width:167px">0.5</td><td style="text-align:center; width:174px">1.3</td></tr><tr><td style="width:121px">Gastric ulcer</td><td style="text-align:center; width:138px">0.0</td><td style="text-align:center; width:124px">1.1</td><td style="text-align:center; width:167px">0.0</td><td style="text-align:center; width:174px">0.0</td></tr><tr><td style="width:121px">Oesophageal ulcer</td><td style="text-align:center; width:138px">0.0</td><td style="text-align:center; width:124px">0.0</td><td style="text-align:center; width:167px">1.5</td><td style="text-align:center; width:174px">0.0</td></tr><tr><td style="width:121px">Musculoskeletal</td><td style="text-align:center; width:138px">&nbsp;</td><td style="text-align:center; width:124px">&nbsp;</td><td style="text-align:center; width:167px">&nbsp;</td><td style="width:174px">&nbsp;</td></tr><tr><td style="width:121px">Musculoskeletal (bone, muscle<br />or joint) pain</td><td style="text-align:center; width:138px">2.9</td><td style="text-align:center; width:124px">3.2</td><td style="text-align:center; width:167px">4.1</td><td style="text-align:center; width:174px">2.5</td></tr><tr><td style="width:121px">Muscle cramp</td><td style="text-align:center; width:138px">0.2</td><td style="text-align:center; width:124px">1.1</td><td style="text-align:center; width:167px">0.0</td><td style="text-align:center; width:174px">1.0</td></tr><tr><td style="width:121px">Neurological</td><td style="text-align:center; width:138px">&nbsp;</td><td style="text-align:center; width:124px">&nbsp;</td><td style="text-align:center; width:167px">&nbsp;</td><td style="width:174px">&nbsp;</td></tr><tr><td style="width:121px">Headache</td><td style="text-align:center; width:138px">0.4</td><td style="text-align:center; width:124px">0.3</td><td style="text-align:center; width:167px">2.6</td><td style="text-align:center; width:174px">1.5</td></tr><tr><td style="width:121px">&nbsp;</td><td style="text-align:center; width:138px">&nbsp;</td><td style="text-align:center; width:124px">&nbsp;</td><td style="text-align:center; width:167px">&nbsp;</td><td style="width:174px">&nbsp;</td></tr></tbody></table><p>Tabulated list of adverse reactions<br />The following adverse experiences have also been reported during clinical studies and/or postmarketing<br />use:<br />Frequencies are defined as: Very common (&ge;1/10), Common (&ge;1/100, &lt;1/10), Uncommon (&ge;1/1,000,<br />&lt;1/100), Rare (&ge;1/10,000, &lt;1/1,000), Very rare (&lt;1/10,000 including isolated cases)</p><table border="1" cellspacing="1" cellpadding="1" style="width:813px"><tbody><tr><td style="width:157px">System organ class</td><td style="width:99px">Frequency</td><td style="width:556px">Adverse reactions</td></tr><tr><td style="width:157px">Immune system disorders</td><td style="width:99px">Rare</td><td style="width:556px">hypersensitivity reactions including urticaria and angioedema</td></tr><tr><td style="width:157px">Metabolism and nutrition<br />disorders</td><td style="width:99px">Rare</td><td style="width:556px">symptomatic hypocalcaemia, often in association with<br />predisposing conditions&sect;</td></tr><tr><td style="width:157px">Nervous system disorders</td><td style="width:99px">Common</td><td style="width:556px">headache, dizzinesst</td></tr><tr><td style="width:157px">&nbsp;</td><td style="width:99px">Uncommon</td><td style="width:556px">dysgeusiat</td></tr><tr><td style="width:157px"><em>Eye disorders</em></td><td style="width:99px">Uncommon</td><td style="width:556px">eye inflammation (uveitis, scleritis, or episcleritis)</td></tr><tr><td style="width:157px">Ear and labyrinth disorders</td><td style="width:99px">Common</td><td style="width:556px">vertigo&dagger;</td></tr><tr><td style="width:157px">&nbsp;</td><td style="width:99px">Very Rare</td><td style="width:556px">osteonecrosis of the external auditory canal<br />(bisphosphonate class adverse reaction)</td></tr><tr><td style="width:157px">Gastrointestinal disorders</td><td style="width:99px">Common</td><td style="width:556px">abdominal pain, dyspepsia, constipation, diarrhoea, flatulence, oesophageal ulcer*, dysphagia*, abdominal distension, acid regurgitation</td></tr><tr><td style="width:157px">&nbsp;</td><td style="width:99px">Uncommon</td><td style="width:556px">nausea, vomiting, gastritis, oesophagitis*, oesophageal<br />erosions*, melena<sup>&dagger;</sup></td></tr><tr><td style="width:157px">&nbsp;</td><td style="width:99px">Rare</td><td style="width:556px">oesophageal stricture*, oropharyngeal ulceration*, upper gastrointestinal PUBs (perforation, ulcers, bleeding) &sect;</td></tr><tr><td style="width:157px">Skin and subcutaneous<br />tissue disorders</td><td style="width:99px">Common</td><td style="width:556px">alopecia<sup>&dagger;</sup>, pruritus<sup>&dagger;</sup></td></tr><tr><td style="width:157px">&nbsp;</td><td style="width:99px">Uncommon</td><td style="width:556px">rash, erythema</td></tr><tr><td style="width:157px">&nbsp;</td><td style="width:99px">Rare</td><td style="width:556px"><p>rash with photosensitivity, severe skin reactions including&nbsp;</p><p>Stevens-Johnson syndrome and toxic epidermal necrolysis<sup>&Dagger;</sup></p></td></tr><tr><td style="width:157px">Musculoskeletal and<br />connective tissue disorders</td><td style="width:99px">Very<br />Common</td><td style="width:556px">musculoskeletal (bone, muscle or joint) pain which is sometimes severe<sup>&dagger;&sect;</sup></td></tr><tr><td style="width:157px">&nbsp;</td><td style="width:99px">Common</td><td style="width:556px">joint swelling<sup>&dagger;</sup></td></tr><tr><td style="width:157px">&nbsp;</td><td style="width:99px">Rare</td><td style="width:556px">osteonecrosis of the jaw&Dagger;&sect;; atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction)</td></tr><tr><td style="width:157px">General disorders and<br />administration site<br />conditions</td><td style="width:99px">Common</td><td style="width:556px">asthenia<sup>&dagger;</sup>, peripheral oedema<sup>&dagger;</sup></td></tr><tr><td style="width:157px">&nbsp;</td><td style="width:99px">Uncommon</td><td style="width:556px">transient symptoms as in an acute-phase response (myalgia, malaise and rarely, fever), typically in association with initiation of treatment&dagger;</td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&sect;See section 4.4<br />&dagger;Frequency in Clinical Trials was similar in the medicinal product and placebo group.<br />*See sections 4.2 and 4.4<br />&Dagger;This adverse reaction was identified through post-marketing surveillance. The frequency of rare was<br />estimated based on relevant clinical trials.</p><p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety<br />Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Hypocalcaemia, hypophosphataemia and upper gastro-intestinal adverse reactions, such as upset<br />stomach, heartburn, oesophagitis, gastritis, or ulcer, may result from oral overdose.</p><p>Management<br />No specific information is available on the treatment of overdose with alendronate. Milk or antacids<br />should be given to bind alendronate. Owing to the risk of oesophageal irritation, vomiting should not be<br />induced and the patient should remain fully upright.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Bisphosphonate, for the treatment of bone diseases<br />ATC Code: M05B A04<br />Mechanism of action<br />The active ingredient of Alendronate, alendronate sodium trihydrate, is a bisphosphonate that inhibits<br />osteoclastic bone resorption with no direct effect on bone formation. Preclinical studies have shown</p><p>preferential localisation of alendronate to sites of active resorption. Activity of osteoclasts is inhibited,<br />but recruitment or attachment of osteoclasts is not affected. The bone formed during treatment with<br />alendronate is of normal quality.<br />Clinical efficacy and safety<br />Treatment of postmenopausal osteoporosis</p><p>Osteoporosis is defined as BMD of the spine or hip 2.5 SD below the mean value of a normal<br />young population or as a previous fragility fracture, irrespective of BMD.<br />The therapeutic equivalence of Alendronate Once Weekly 70 mg (n=519) and alendronate 10 mg daily<br />(n=370) was demonstrated in a one-year multicentre study of postmenopausal women with<br />osteoporosis. The mean increases from baseline in lumbar spine BMD at one year were 5.1% (95% CI:<br />4.8, 5.4%) in the 70 mg once-weekly group and 5.4% (95% CI: 5.0, 5.8%) in the 10 mg daily group.<br />The mean BMD increases were 2.3% and 2.9% at the femoral neck and 2.9% and 3.1% at the total hip<br />in the 70 mg once weekly and 10 mg daily groups, respectively. The two treatment groups were also<br />similar with regard to BMD increases at other skeletal sites.</p><p>The effects of alendronate on bone mass and fracture incidence in postmenopausal women were<br />examined in two initial efficacy studies of identical design (n=994) as well as in the Fracture<br />Intervention Trial (FIT: n=6,459).</p><p>In the initial efficacy studies, the mean bone mineral density (BMD) increases with alendronate 10<br />mg/day relative to placebo at three years were 8.8%, 5.9% and 7.8% at the spine, femoral neck and<br />trochanter, respectively. Total body BMD also increased significantly. There was a 48% reduction<br />(alendronate 3.2% vs placebo 6.2%) in the proportion of patients treated with alendronate experiencing<br />one or more vertebral fractures relative to those treated with placebo. In the two-year extension of these<br />studies BMD at the spine and trochanter continued to increase and BMD at the femoral neck and total<br />body were maintained.</p><p>FIT consisted of two placebo-controlled studies using alendronate daily (5 mg daily for two years and<br />10 mg daily for either one or two additional years):</p><p>&bull; FIT 1: A three-year study of 2,027 patients who had at least one baseline vertebral (compression)<br />fracture. In this study alendronate daily reduced the incidence of &ge;1 new vertebral fracture by 47%<br />(alendronate 7.9% vs. placebo 15.0%). In addition, a statistically significant reduction was found in the<br />incidence of hip fractures (1.1% vs. 2.2%, a reduction of 51%).</p><p>&bull; FIT 2: A four-year study of 4,432 patients with low bone mass but without a baseline vertebral<br />fracture. In this study, a significant difference was observed in the analysis of the subgroup of<br />osteoporotic women (37% of the global population who correspond with the above definition of<br />osteoporosis) in the incidence of hip fractures (alendronate 1.0% vs. placebo 2.2%, a reduction of 56%)<br />and in the incidence of &ge;1 vertebral fracture (2.9% vs. 5.8%, a reduction of 50%).</p><p>Laboratory test findings<br />In clinical studies, asymptomatic, mild and transient decreases in serum calcium and phosphate were<br />observed in approximately 18 and 10%, respectively, of patients taking alendronate 10 mg/day versus<br />approximately 12 and 3% of those taking placebo. However, the incidences of decreases in serum<br />calcium to &lt;8.0 mg/dl (2.0 mmol/l) and serum phosphate to &le;2.0 mg/dl (0.65 mmol/l) were similar in<br />both treatment groups.</p><p>Paediatric population:<br />Alendronate sodium has been studied in a small number of patients with osteogenesis imperfecta under<br />the age of 18 years. Results are insufficient to support the use of alendronate sodium in paediatric<br />patients with osteogenesis imperfecta.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Relative to an intravenous reference dose, the oral mean bioavailability of alendronate in women was<br />0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours<br />before a standardised breakfast. Bioavailability was decreased similarly to an estimated 0.46% and<br />0.39% when alendronate was administered one hour or half an hour before a standardised breakfast. In<br />osteoporosis studies, alendronate was effective when administered at least 30 minutes before the first<br />food or beverage of the day.</p><p>Bioavailability was negligible whether alendronate was administered with, or up to two hours after, a<br />standardised breakfast. Concomitant administration of alendronate with coffee or orange juice reduced<br />bioavailability by approximately 60%.</p><p>In healthy subjects, oral prednisone (20 mg three times daily for five days) did not produce a clinically<br />meaningful change in oral bioavailability of alendronate (a mean increase ranging from 20% to 44%).</p><p>Distribution<br />Studies in rats show that alendronate transiently distributes to soft tissues following 1 mg/kg<br />intravenous administration but is then rapidly redistributed to bone or excreted in the urine. The mean<br />steady-state volume of distribution, exclusive of bone, is at least 28 litres in humans. Concentrations of<br />drug in plasma following therapeutic oral doses are too low for analytical detection (&lt;5 ng/ml). Protein<br />binding in human plasma is approximately 78%.</p><p>Biotransformation<br />There is no evidence that alendronate is metabolised in animals or humans.</p><p>Elimination<br />Following a single intravenous dose of [14C] alendronate, approximately 50% of the radioactivity was<br />excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces.<br />Following a single 10 mg intravenous dose, the renal clearance of alendronate was 71 ml/min, and<br />systemic clearance did not exceed 200 ml/min. Plasma concentrations fell by more than 95% within six<br />hours following intravenous administration. The terminal half-life in humans is estimated to exceed ten<br />years, reflecting release of alendronate from the skeleton. Alendronate is not excreted through the<br />acidic or basic transport systems of the kidney in rats, and thus it is not anticipated to interfere with the<br />excretion of other medicinal products by those systems in humans.</p><p><br />Renal impairment<br />Preclinical studies show that the drug that is not deposited in bone is rapidly excreted in the urine. No<br />evidence of saturation of bone uptake was found after chronic dosing with cumulative intravenous<br />doses up to 35 mg/kg in animals. Although no clinical information is available, it is likely that, as in<br />animals, elimination of alendronate via the kidney will be reduced in patients with impaired renal<br />function. Therefore, somewhat greater accumulation of alendronate in bone might be expected in<br />patients with impaired renal function (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Studies in rats have<br />shown that treatment with alendronate during pregnancy was associated with dystocia in dams during<br />parturition which was related to hypocalcaemia. In studies, rats given high doses showed an increased<br />incidence of incomplete foetal ossification. The relevance to humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose<br />Lactose<br />Croscarmellose sodium<br />Magnesium stearate<br />Colloidal Silicon Dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum/aluminum blisters.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Address:  P.O.Box 6267, Plot No : ME 1:3, Industrial Area, Phase V, Jeddah, 21442,
Saudi Arabia
Phone : +966126081111
Fax : +966126081222
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>